Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate

Protalix BioTherapeutics reported a Q4 EPS of $(0.06), missing the analyst estimate of $0.04 by 250%. This represents a 166.67% decrease from earnings of $0.09 per share in the same period last year. The company's quarterly sales were $9.300 million, falling short of the $16.918 million estimate by 45.03%, and showing a 48.95% decline from $18.218 million in the previous year.